NCT05701007View on ClinicalTrials.gov

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

CompletedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

February 13, 2023

Primary Completion Date

April 10, 2024

Study Completion Date

April 10, 2024

Conditions
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
DRUG

abiraterone

mCRPC

DRUG

enzalutamide

mCRPC

DRUG

docetaxel

mCRPC

DRUG

apalutamide

mCRPC

DRUG

cabazitaxel

mCRPC

DRUG

Radium-223

mCRPC

DRUG

Lutetium-177

mCRPC

DRUG

degarelix

mCSPC

DRUG

goserelin

mCSPC

DRUG

leuprorelin

mCSPC

DRUG

triptorelin

mCSPC

Trial Locations (1)

Unknown

Pfizer, Helsinki

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05701007 - Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | Biotech Hunter | Biotech Hunter